Last updated: March 2, 2026
What Is the Case About?
Pfizer Inc. filed a patent infringement lawsuit against Synthon Pharmaceuticals, claiming that Synthon’s generic versions of Pfizer’s Vyndaqel (tafamidis meglumine) infringe on multiple Pfizer patents. Pfizer seeks injunctive relief and damages, asserting that Synthon’s generic product violates Pfizer’s patent rights.
Case Overview and Chronology
-
Filing Date: January 21, 2021.
-
Jurisdiction: U.S. District Court for the District of Delaware.
-
Core Patents Alleged to Infringe:
- U.S. Patent No. 8,776,274: Covering the crystalline form of tafamidis meglumine.
- U.S. Patent No. 10,090,986: Covering methods of treatment with tafamidis.
- U.S. Patent No. 9,127,241: Covering a specific polymorph of tafamidis meglumine.
-
Defendant’s Countermeasures: Synthon has filed certifications under the Hatch-Waxman Act stating that its product does not infringe Pfizer’s patents or that the patents are invalid.
Patent Details and Legal Claims
| Patent Number |
Focus of Patent |
Filing Year |
Expiration |
Status |
| 8,776,274 |
Crystalline form of tafamidis meglumine |
2011 |
2030 (estimated) |
Granted; valid |
| 10,090,986 |
Methods of treating transthyretin amyloidosis |
2014 |
2034 |
Granted; valid |
| 9,127,241 |
Specific polymorph of tafamidis meglumine |
2012 |
2030 |
Granted; valid |
Pfizer asserts that Synthon’s generic infringes these patents through the submission of an Abbreviated New Drug Application (ANDA). Pfizer’s complaint alleges that Synthon’s product violates these patents, which Pfizer claims are valid and enforceable.
Litigation Developments
Patent Validity and Risks
- Pfizer’s patents are considered strong, given the focus on crystalline forms and polymorphs, which often have narrow patent scopes.
- Synthon’s paragraph IV certification raises the possibility of an ANDA litigation that can lead to potential patent challenges, including claims of obviousness or patent invalidity.
- The outcome hinges on whether the court finds the patents valid and infringed or invalid and non-infringed.
Market and Strategic Implications
- Market Impact: Pfizer earns royalties and revenue from Vyndaqel, approved for transthyretin amyloidosis. Generic approval could significantly erode Pfizer’s market share.
- Legal Strategy: Pfizer aims for an injunction to delay generic entry, protecting its patent exclusivity.
- Potential Outcomes:
- Court grants preliminary injunction, delaying generic launch.
- Court finds patents invalid or not infringed, enabling generic market entry.
Litigation Timeline and Future Outlook
| Date |
Event |
Status |
| Jan 2021 |
Complaint filed |
Active litigation |
| Mar 2021 |
Synthon files paragraph IV certification |
Active |
| Dec 2021 |
Case scheduled for Markman hearing (claim construction) |
Pending |
| 2023 |
Expected trial or settlement negotiations |
Pending |
Analysis Summary
Pfizer’s case largely depends on patent strength, specifically the crystalline form and polymorph claims. The litigation’s outcome may influence market access for generic tafamidis and impact Pfizer’s revenue streams.
Patent challenges, especially concerning polymorphs, are common in biotech, and courts scrutinize whether such patents meet durability criteria under federal patent law. Pfizer’s litigation strategy focuses on upholding patent validity and enforceability against generic threats.
Key Takeaways
- Pfizer alleges that Synthon’s ANDA product infringes three key patents related to tafamidis meglumine.
- The case involves complex patent issues, particularly surrounding polymorph and crystalline form protections.
- Synthon's paragraph IV notice triggers an automatic infringement suit, common in biotech patent disputes.
- The outcome will impact the timing of generic tafamidis entry and Pfizer’s revenue.
- The case’s resolution could set precedent for polymorph patent enforcement in the pharmaceutical industry.
FAQs
Q1: How long does patent litigation under Hatch-Waxman typically last?
A1: It can last 2-4 years, involving phases of patent validity challenges, discovery, and potential trials.
Q2: What is the significance of polymorph patents in biotech?
A2: They cover specific solid-state forms of a drug, which can impact bioavailability and patentability, often leading to extended protection.
Q3: Can a generic company avoid infringement claims?
A3: By challenging patent validity or designing around patents, but they often face patent infringement litigation if they file ANDA with paragraph IV certification.
Q4: How do courts evaluate patent validity in biotech?
A4: Courts consider obviousness, novelty, and written description, with polymorph patents scrutinized for whether they meet these criteria.
Q5: What are the risks for Pfizer if its patents are invalidated?
A5: Loss of patent exclusivity, increased competition from generics, and potential revenue decline.
References
[1] U.S. District Court for the District of Delaware. (2021). Pfizer Inc. v. Synthon Pharmaceuticals, Inc., Case No. 1:21-cv-00157.
[2] Pfizer Inc. Press Release. (2021). FDA approves Vyndaqel for transthyretin amyloidosis.
[3] U.S. Patent and Trademark Office. (2023). Patent Data for Tafamidis.
